KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Liabilities and Shareholders Equity: 2018-2024

Historic Liabilities and Shareholders Equity for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $343.8 million.

  • Esperion Therapeutics' Liabilities and Shareholders Equity rose 15.89% to $364.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 10.73%. This contributed to the annual value of $343.8 million for FY2024, which is 67.07% up from last year.
  • Esperion Therapeutics' Liabilities and Shareholders Equity amounted to $343.8 million in FY2024, which was up 67.07% from $205.8 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' Liabilities and Shareholders Equity peaked at $381.6 million during FY2021, and registered a low of $205.8 million during FY2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $265.9 million, with a median of $247.9 million in 2022.
  • As far as peak fluctuations go, Esperion Therapeutics' Liabilities and Shareholders Equity crashed by 35.02% in 2022, and later soared by 67.07% in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Liabilities and Shareholders Equity stood at $353.3 million in 2020, then increased by 8.02% to $381.6 million in 2021, then slumped by 35.02% to $247.9 million in 2022, then dropped by 17.00% to $205.8 million in 2023, then soared by 67.07% to $343.8 million in 2024.